GC2 – Surgical outcomes and neoadjuvant safety with perioperative durvalumab for muscle-invasive bladder cancer (NIAGARA)

IF 25.2 1区医学 Q1 UROLOGY & NEPHROLOGY

European urology Pub Date : 2025-09-24 DOI:10.1016/j.eururo.2025.09.4122

J.W.F. Catto, H. Al-Ahmadie, M.S. van der Heijden, T. Powles, M.D. Galsky, H. Nishiyama, T.Q. Vu, L. Antonuzzo, P. Wiechno, V. Atduev, A.G. Kann, T.H. Kim, C. Suárez, A.Font Pous, C.H. Chang, F. Roghmann, R. de Wit, J.H. Ku, D.D.Almeida Preto, Y. Zakharia, W. Xin, S. Ho, K. Bigos, J.J. Meeks

引用次数: 0

查看原文本刊更多论文

GC2 - durvalumab治疗肌肉浸润性膀胱癌的围手术期手术效果和新辅助安全性（NIAGARA）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology 医学-泌尿学与肾脏学

CiteScore

43.00

自引率

2.60%

发文量

1753

审稿时长

23 days

期刊介绍： European Urology is a peer-reviewed journal that publishes original articles and reviews on a broad spectrum of urological issues. Covering topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, the journal also highlights recent advances in techniques, instrumentation, surgery, and pediatric urology. This comprehensive approach provides readers with an in-depth guide to international developments in urology.